within Pharmacolibrary.Drugs.ATC.L;

model L04AG11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.193 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.00505,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Anifrolumab is a fully human monoclonal antibody that targets the type I interferon receptor subunit 1 (IFNAR1), blocking activity of type I interferons implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is approved for the treatment of moderate to severe SLE in adults who are receiving standard therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics reported in adult SLE patients (including males and females) after intravenous administration.</p><h4>References</h4><ol><li><p>Tummala, R, et al., &amp; Santiago, L (2018). Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. <i>Lupus science &amp; medicine</i> 5(1) e000252–None. DOI:<a href=&quot;https://doi.org/10.1136/lupus-2017-000252&quot;>10.1136/lupus-2017-000252</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29644080/&quot;>https://pubmed.ncbi.nlm.nih.gov/29644080</a></p></li><li><p>Tang, W, et al., &amp; MacDonald, A (2023). Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. <i>Clinical pharmacokinetics</i> 62(5) 655–671. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01238-2&quot;>10.1007/s40262-023-01238-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37148484/&quot;>https://pubmed.ncbi.nlm.nih.gov/37148484</a></p></li><li><p>Almquist, J, et al., &amp; Chia, YL (2022). Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. <i>Journal of clinical pharmacology</i> 62(9) 1106–1120. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2055&quot;>10.1002/jcph.2055</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35383948/&quot;>https://pubmed.ncbi.nlm.nih.gov/35383948</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG11;
